Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8N653

UPID:
LZTR1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8N653; Q14776; Q20WK0

BACKGROUND:
The Leucine-zipper-like transcriptional regulator 1 is a key component of the BCR E3 ubiquitin-protein ligase complex, mediating the ubiquitination of Ras proteins. This action serves as a critical checkpoint in the negative regulation of the RAS-MAPK pathway by modulating Ras protein levels and membrane association.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Leucine-zipper-like transcriptional regulator 1 could open doors to potential therapeutic strategies. Its involvement in the pathogenesis of gliomas, Schwannomatosis 2, and Noonan syndromes 10 and 2 underscores its significance in disease mechanisms and therapeutic potential.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.